Identification

Name
Cisapride
Accession Number
DB00604  (APRD00454)
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.

Structure
Thumb
Synonyms
  • Cisaprid
  • Cisaprida
  • Cisapride
  • Cisapridum
External IDs
R 51619 / R-51,619 / R-51619
Product Ingredients
IngredientUNIICASInChI Key
Cisapride monohydrateVZV0A4I38W260779-88-2QBYYXIDJOFZORM-LBPAWUGGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Prepulsid Sus 1mg/mlSuspension1 mgOralJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1992-12-312000-08-25Canada
Prepulsid Tab 10mgTablet10 mgOralJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1990-12-312000-08-25Canada
Prepulsid Tab 20mgTablet20 mgOralJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1993-12-312000-08-25Canada
Prepulsid Tab 5mgTablet5 mgOralJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1990-12-312000-08-25Canada
International/Other Brands
Enteropride / Kinestase / Prepulsid (Janssen-Ortho) / Pridesia / Propulsid (Janssen-Ortho) / Propulsid Quicksolv (Janssen-Ortho)
Categories
UNII
UVL329170W
CAS number
81098-60-4
Weight
Average: 465.945
Monoisotopic: 465.183062343
Chemical Formula
C23H29ClFN3O4
InChI Key
DCSUBABJRXZOMT-IRLDBZIGSA-N
InChI
InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1
IUPAC Name
4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide
SMILES
CO[[email protected]]1CN(CCCOC2=CC=C(F)C=C2)CC[[email protected]]1NC(=O)C1=CC(Cl)=C(N)C=C1OC

Pharmacology

Indication

For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.

Structured Indications
Not Available
Pharmacodynamics

Cisapride is a parasympathomimetic which acts as a serotonin 5-HT4 agonist. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. Cisapride stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Cisapride increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder. Cisapride does not induce muscarinic or nicotinic receptor stimulation, nor does it inhibit acetylcholinesterase activity.

Mechanism of action

Cisapride acts through the stimulation of the serotonin 5-HT4 receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.

TargetActionsOrganism
A5-hydroxytryptamine receptor 4
agonist
Human
A5-hydroxytryptamine receptor 3A
agonist
Human
A5-hydroxytryptamine receptor 2A
agonist
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
Absorption

Cisapride is rapidly absorbed after oral administration, with an absolute bioavailability of 35-40%.

Volume of distribution
Not Available
Protein binding

97.5%

Metabolism

Hepatic. Extensively metabolized via cytochrome P450 3A4 enzyme.

Route of elimination
Not Available
Half life

6-12 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Cisapride can be increased when it is combined with 1,10-Phenanthroline.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of Cisapride can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe serum concentration of Cisapride can be increased when it is combined with 2-mercaptobenzothiazole.Vet Approved
3,4-DichloroisocoumarinThe serum concentration of Cisapride can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Cisapride can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AbirateroneThe serum concentration of Cisapride can be increased when it is combined with Abiraterone.Approved
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
AlogliptinThe serum concentration of Cisapride can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Cisapride can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Cisapride.Approved
AmiodaroneThe metabolism of Cisapride can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the arrhythmogenic activities of Cisapride.Approved
AmorolfineThe serum concentration of Cisapride can be increased when it is combined with Amorolfine.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Cisapride.Approved
Amphotericin BThe serum concentration of Cisapride can be increased when it is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Cisapride can be increased when it is combined with Amprenavir.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Cisapride.Approved
AnidulafunginThe serum concentration of Cisapride can be increased when it is combined with Anidulafungin.Approved, Investigational
Antithrombin III humanThe serum concentration of Cisapride can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Cisapride can be increased when it is combined with Apixaban.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
AprepitantThe serum concentration of Cisapride can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Cisapride can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArformoterolArformoterol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
ArgatrobanThe serum concentration of Cisapride can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
ArmodafinilThe metabolism of Cisapride can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Cisapride can be increased when it is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Cisapride can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Cisapride can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Cisapride.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Cisapride is combined with Atorvastatin.Approved
AzithromycinThe metabolism of Cisapride can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Cisapride can be increased when it is combined with Bafilomycin A1.Experimental
BatimastatThe serum concentration of Cisapride can be increased when it is combined with Batimastat.Experimental
BedaquilineBedaquiline may increase the QTc-prolonging activities of Cisapride.Approved
BenazeprilThe serum concentration of Cisapride can be increased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Cisapride can be increased when it is combined with Benzamidine.Experimental
Benzoic AcidThe serum concentration of Cisapride can be increased when it is combined with Benzoic Acid.Approved
BepridilCisapride may increase the QTc-prolonging activities of Bepridil.Approved, Withdrawn
BicalutamideThe serum concentration of Cisapride can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Cisapride can be increased when it is combined with Bifonazole.Approved, Investigational
BivalirudinThe serum concentration of Cisapride can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Cisapride can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
BosentanThe serum concentration of Cisapride can be decreased when it is combined with Bosentan.Approved, Investigational
Brefeldin AThe serum concentration of Cisapride can be increased when it is combined with Brefeldin A.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cisapride.Approved, Investigational
BuserelinBuserelin may increase the QTc-prolonging activities of Cisapride.Approved
ButenafineThe serum concentration of Cisapride can be increased when it is combined with Butenafine.Approved
ButoconazoleThe serum concentration of Cisapride can be increased when it is combined with Butoconazole.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cisapride.Approved
CaffeineThe metabolism of Cisapride can be decreased when combined with Caffeine.Approved
CamostatThe serum concentration of Cisapride can be increased when it is combined with Camostat.Experimental
CandicidinThe serum concentration of Cisapride can be increased when it is combined with Candicidin.Withdrawn
CandoxatrilThe serum concentration of Cisapride can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Cisapride can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Cisapride can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe serum concentration of Cisapride can be increased when it is combined with Capric acid.Experimental
CaptoprilThe serum concentration of Cisapride can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Cisapride can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe metabolism of Cisapride can be decreased when combined with Carbomycin.Vet Approved
CaspofunginThe serum concentration of Cisapride can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Cisapride can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Cisapride can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cisapride.Withdrawn
CeruleninThe serum concentration of Cisapride can be increased when it is combined with Cerulenin.Approved
ChloramphenicolThe metabolism of Cisapride can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
ChloroxineThe serum concentration of Cisapride can be increased when it is combined with Chloroxine.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
CholecalciferolThe metabolism of Cisapride can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Cisapride can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Cisapride can be increased when it is combined with Chymostatin.Experimental
CiclopiroxThe serum concentration of Cisapride can be increased when it is combined with Ciclopirox.Approved, Investigational
CilastatinThe serum concentration of Cisapride can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Cisapride can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cisapride can be increased when it is combined with Cimetidine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
CitalopramThe metabolism of Cisapride can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Cisapride can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cisapride can be decreased when combined with Clemastine.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
ClopidogrelThe metabolism of Cisapride can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Cisapride can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Cisapride.Approved
CobicistatThe serum concentration of Cisapride can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Cisapride can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe serum concentration of Cisapride can be increased when it is combined with Cordycepin.Investigational
CrisaboroleThe metabolism of Cisapride can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Cisapride can be decreased when combined with Crizotinib.Approved
CyclosporineThe serum concentration of Cisapride can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Cisapride can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Cisapride can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Cisapride can be decreased when it is combined with Dabrafenib.Approved
DarexabanThe serum concentration of Cisapride can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Cisapride can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cisapride can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Cisapride can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Cisapride.Approved
DelanzomibThe serum concentration of Cisapride can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Cisapride can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Cisapride can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Cisapride.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Cisapride.Approved
DichloropheneThe serum concentration of Cisapride can be increased when it is combined with Dichlorophene.Vet Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cisapride.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cisapride.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Cisapride.Experimental
DihydroergotamineThe metabolism of Cisapride can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Cisapride can be decreased when combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Cisapride.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Cisapride.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Cisapride.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Cisapride.Approved
DomperidoneThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Domperidone.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Cisapride can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Cisapride.Approved
DoxorubicinThe metabolism of Cisapride can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Cisapride can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cisapride can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
EcabetThe serum concentration of Cisapride can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe serum concentration of Cisapride can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Cisapride can be increased when it is combined with Edoxaban.Approved
EfavirenzThe metabolism of Cisapride can be decreased when combined with Efavirenz.Approved, Investigational
EfinaconazoleThe serum concentration of Cisapride can be increased when it is combined with Efinaconazole.Approved
ElafinThe serum concentration of Cisapride can be increased when it is combined with Elafin.Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Eliglustat.Approved
EnalaprilThe serum concentration of Cisapride can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Cisapride can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Cisapride can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Cisapride can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe serum concentration of Cisapride can be increased when it is combined with Epigallocatechin Gallate.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cisapride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Cisapride.Approved
EribulinEribulin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
ErythromycinThe metabolism of Cisapride can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Cisapride can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Cisapride can be decreased when combined with Esomeprazole.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Cisapride is combined with Ethanol.Approved
EtravirineThe metabolism of Cisapride can be decreased when combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Cisapride.Approved
FaldaprevirThe serum concentration of Cisapride can be increased when it is combined with Faldaprevir.Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Cisapride.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Cisapride.Approved
FelodipineThe metabolism of Cisapride can be decreased when combined with Felodipine.Approved, Investigational
FenticonazoleThe serum concentration of Cisapride can be increased when it is combined with Fenticonazole.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cisapride.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Cisapride.Approved, Withdrawn
FloxuridineThe metabolism of Cisapride can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Cisapride can be increased when it is combined with Fluconazole.Approved
FlucytosineThe serum concentration of Cisapride can be increased when it is combined with Flucytosine.Approved
FluorouracilThe metabolism of Cisapride can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Cisapride can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Flupentixol.Approved, Withdrawn
FlutrimazoleThe serum concentration of Cisapride can be increased when it is combined with Flutrimazole.Experimental
FluvastatinThe metabolism of Cisapride can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Cisapride can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
FosamprenavirThe serum concentration of Cisapride can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cisapride can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Cisapride.Approved
FosinoprilThe serum concentration of Cisapride can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Cisapride can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Cisapride can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Cisapride can be increased when it is combined with Gabexate.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Cisapride.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Cisapride.Approved
GeldanamycinThe serum concentration of Cisapride can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Cisapride can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
GlyphosateThe serum concentration of Cisapride can be increased when it is combined with Glyphosate.Experimental
GM6001The serum concentration of Cisapride can be increased when it is combined with GM6001.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Cisapride.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
GriseofulvinThe serum concentration of Cisapride can be increased when it is combined with Griseofulvin.Approved, Vet Approved
HachimycinThe serum concentration of Cisapride can be increased when it is combined with Hachimycin.Experimental
HaloperidolHaloperidol may increase the QTc-prolonging activities of Cisapride.Approved
HaloproginThe serum concentration of Cisapride can be increased when it is combined with Haloprogin.Approved, Withdrawn
HexetidineThe serum concentration of Cisapride can be increased when it is combined with Hexetidine.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Cisapride.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Cisapride.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Cisapride.Approved
IdelalisibThe serum concentration of Cisapride can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Cisapride can be increased when it is combined with Idraparinux.Investigational
IloperidoneThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Iloperidone.Approved
ImatinibThe metabolism of Cisapride can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Cisapride can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Cisapride.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Cisapride.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Cisapride.Approved
IndinavirThe serum concentration of Cisapride can be increased when it is combined with Indinavir.Approved
IrbesartanThe metabolism of Cisapride can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Cisapride can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe serum concentration of Cisapride can be increased when it is combined with Isoconazole.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
IsoflurophateThe serum concentration of Cisapride can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Cisapride can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Cisapride.Approved
ItraconazoleThe serum concentration of Cisapride can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Cisapride.Approved
IvacaftorThe serum concentration of Cisapride can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Cisapride can be increased when it is combined with Ixazomib.Approved
JosamycinThe metabolism of Cisapride can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe serum concentration of Cisapride can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Cisapride can be decreased when combined with Kitasamycin.Experimental
LapatinibLapatinib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
LeflunomideThe metabolism of Cisapride can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Cisapride.Approved
LepirudinThe serum concentration of Cisapride can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Cisapride can be increased when it is combined with Letaxaban.Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
LidocaineThe metabolism of Cisapride can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Cisapride can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Cisapride can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Cisapride.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Cisapride.Approved
LobeglitazoneThe metabolism of Cisapride can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe serum concentration of Cisapride can be increased when it is combined with Lopinavir.Approved
LosartanThe metabolism of Cisapride can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Cisapride can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cisapride can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cisapride can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Cisapride.Illicit, Investigational, Withdrawn
ManidipineThe metabolism of Cisapride can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Cisapride.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Cisapride.Approved
MelagatranThe serum concentration of Cisapride can be increased when it is combined with Melagatran.Experimental
MepartricinThe serum concentration of Cisapride can be increased when it is combined with Mepartricin.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Cisapride.Experimental
MethadoneMethadone may increase the QTc-prolonging activities of Cisapride.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Cisapride.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cisapride.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Cisapride.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cisapride.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Cisapride.Approved
MevastatinThe serum concentration of Cisapride can be increased when it is combined with Mevastatin.Experimental
MexiletineThe metabolism of Cisapride can be decreased when combined with Mexiletine.Approved
MicafunginThe serum concentration of Cisapride can be increased when it is combined with Micafungin.Approved, Investigational
MiconazoleThe serum concentration of Cisapride can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Cisapride can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Cisapride can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe serum concentration of Cisapride can be increased when it is combined with Miltefosine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Cisapride.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Cisapride.Approved
MitotaneThe serum concentration of Cisapride can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Cisapride can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Cisapride can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Cisapride can be increased when it is combined with Moexipril.Approved
MonensinThe serum concentration of Cisapride can be increased when it is combined with Monensin.Vet Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
MyxothiazolThe serum concentration of Cisapride can be increased when it is combined with Myxothiazol.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cisapride can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Cisapride can be increased when it is combined with Nafamostat.Approved, Investigational
NaftifineThe serum concentration of Cisapride can be increased when it is combined with Naftifine.Approved
NatamycinThe serum concentration of Cisapride can be increased when it is combined with Natamycin.Approved
NefazodoneThe serum concentration of Cisapride can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Cisapride can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cisapride can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cisapride can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Cisapride.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Cisapride.Approved, Investigational
NicotineThe metabolism of Cisapride can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cisapride.Approved
NifuratelThe serum concentration of Cisapride can be increased when it is combined with Nifuratel.Experimental
Nikkomycin ZThe serum concentration of Cisapride can be increased when it is combined with Nikkomycin Z.Investigational
NilotinibThe metabolism of Cisapride can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe serum concentration of Cisapride can be increased when it is combined with Nitroaspirin.Investigational
NitroxolineThe serum concentration of Cisapride can be increased when it is combined with Nitroxoline.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Cisapride.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Cisapride.Approved
NystatinThe serum concentration of Cisapride can be increased when it is combined with Nystatin.Approved, Vet Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Cisapride.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
OlaparibThe metabolism of Cisapride can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Cisapride can be decreased when combined with Oleandomycin.Vet Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Cisapride.Approved
OmapatrilatThe serum concentration of Cisapride can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Cisapride can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe serum concentration of Cisapride can be increased when it is combined with Omoconazole.Experimental
OndansetronOndansetron may increase the QTc-prolonging activities of Cisapride.Approved
OsimertinibThe serum concentration of Cisapride can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Cisapride can be increased when it is combined with Otamixaban.Investigational
OxiconazoleThe serum concentration of Cisapride can be increased when it is combined with Oxiconazole.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
pafuramidineThe serum concentration of Cisapride can be increased when it is combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Cisapride can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
PantoprazoleThe metabolism of Cisapride can be decreased when combined with Pantoprazole.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Cisapride.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Cisapride.Approved
Peginterferon alfa-2bThe serum concentration of Cisapride can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe serum concentration of Cisapride can be increased when it is combined with Pentamidine.Approved
PentobarbitalThe metabolism of Cisapride can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Cisapride.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Cisapride.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Cisapride can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe metabolism of Cisapride can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Cisapride can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Cisapride can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Pimozide.Approved
PioglitazoneThe metabolism of Cisapride can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cisapride.Approved
PosaconazoleThe serum concentration of Cisapride can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cisapride.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Cisapride.Approved
PrimidoneThe metabolism of Cisapride can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Cisapride can be increased when it is combined with Prinomastat.Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Cisapride.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Cisapride.Approved
PropofolPropofol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the arrhythmogenic activities of Cisapride.Approved
PyrimethamineThe metabolism of Cisapride can be decreased when combined with Pyrimethamine.Approved, Vet Approved
PyrrolnitrinThe serum concentration of Cisapride can be increased when it is combined with Pyrrolnitrin.Experimental
QuazepamThe serum concentration of Cisapride can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Cisapride can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Quinidine.Approved
QuinineThe metabolism of Cisapride can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Cisapride can be decreased when combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Cisapride can be increased when it is combined with Racecadotril.Investigational
RadicicolThe serum concentration of Cisapride can be increased when it is combined with Radicicol.Experimental
RamiprilThe serum concentration of Cisapride can be increased when it is combined with Ramipril.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
RemikirenThe serum concentration of Cisapride can be increased when it is combined with Remikiren.Approved
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Cisapride.Approved
RifabutinThe metabolism of Cisapride can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cisapride can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cisapride can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Cisapride.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
RitonavirThe serum concentration of Cisapride can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Cisapride can be increased when it is combined with Rivaroxaban.Approved
RopiniroleThe metabolism of Cisapride can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Cisapride can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cisapride.Approved
RoxithromycinThe metabolism of Cisapride can be decreased when combined with Roxithromycin.Approved, Investigational, Withdrawn
S-3304The serum concentration of Cisapride can be increased when it is combined with S-3304.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
Salicylhydroxamic AcidThe serum concentration of Cisapride can be increased when it is combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe serum concentration of Cisapride can be increased when it is combined with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Cisapride.Approved
SaquinavirThe serum concentration of Cisapride can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Cisapride can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Cisapride can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe serum concentration of Cisapride can be increased when it is combined with Sertaconazole.Approved
SertralineSertraline may increase the QTc-prolonging activities of Cisapride.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
SildenafilThe metabolism of Cisapride can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cisapride can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cisapride can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cisapride.Approved
SinefunginThe serum concentration of Cisapride can be increased when it is combined with Sinefungin.Experimental
SirolimusThe serum concentration of Cisapride can be increased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Cisapride can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Cisapride can be increased when it is combined with Sivelestat.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Cisapride.Approved
SolithromycinThe metabolism of Cisapride can be decreased when combined with Solithromycin.Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Cisapride.Approved
SpiraprilThe serum concentration of Cisapride can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Cisapride can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Cisapride can be increased when it is combined with Stiripentol.Approved
SulconazoleThe serum concentration of Cisapride can be increased when it is combined with Sulconazole.Approved
SulfadiazineThe metabolism of Cisapride can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Cisapride.Approved
SulfisoxazoleThe metabolism of Cisapride can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Cisapride is combined with Sulpiride.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Cisapride.Approved
TavaboroleThe serum concentration of Cisapride can be increased when it is combined with Tavaborole.Approved
TelaprevirThe serum concentration of Cisapride can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Cisapride.Approved
TelithromycinThe metabolism of Cisapride can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Cisapride can be increased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Cisapride can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe serum concentration of Cisapride can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Cisapride.Approved
TerconazoleThe serum concentration of Cisapride can be increased when it is combined with Terconazole.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Cisapride.Experimental
TeriflunomideThe serum concentration of Cisapride can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Tetrabenazine.Approved
TheophyllineThe metabolism of Cisapride can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cisapride.Approved, Withdrawn
ThiorphanThe serum concentration of Cisapride can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Cisapride can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Cisapride.Approved
ThymolThe serum concentration of Cisapride can be increased when it is combined with Thymol.Approved
TicagrelorThe metabolism of Cisapride can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Cisapride can be decreased when combined with Ticlopidine.Approved
TioconazoleThe serum concentration of Cisapride can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Cisapride can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Cisapride.Approved
TocilizumabThe serum concentration of Cisapride can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Cisapride can be decreased when combined with Tolbutamide.Approved
TolciclateThe serum concentration of Cisapride can be increased when it is combined with Tolciclate.Experimental
TolnaftateThe serum concentration of Cisapride can be increased when it is combined with Tolnaftate.Approved, Vet Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
TopiramateThe metabolism of Cisapride can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Cisapride can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Cisapride.Approved, Investigational
TrandolaprilThe serum concentration of Cisapride can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Cisapride can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
TrimetrexateThe serum concentration of Cisapride can be increased when it is combined with Trimetrexate.Approved, Investigational
TrimipramineTrimipramine may increase the QTc-prolonging activities of Cisapride.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Cisapride.Approved, Vet Approved
TylosinThe metabolism of Cisapride can be decreased when combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Cisapride can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Cisapride.Approved, Experimental
UlinastatinThe serum concentration of Cisapride can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe metabolism of Cisapride can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Cisapride can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Cisapride.Approved
VemurafenibThe serum concentration of Cisapride can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Cisapride.Approved
VerapamilThe metabolism of Cisapride can be decreased when combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Cisapride.Approved
VildagliptinThe serum concentration of Cisapride can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe serum concentration of Cisapride can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Cisapride.Approved, Investigational
XimelagatranThe serum concentration of Cisapride can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Cisapride can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Cisapride can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Cisapride can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Cisapride can be increased when it is combined with Zofenopril.Experimental
ZucapsaicinThe metabolism of Cisapride can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment, grapefruit can significantly increase serum levels of this product.
  • Increases absorption, take 30 minutes before a meal.

References

Synthesis Reference

Alfons Gaston Maria De Knaep, Luc Jozef Raphael Moens, Max Rey, "Synthesis of cisapride." U.S. Patent US6218542, issued January, 1988.

US6218542
General References
  1. Pearce RE, Gotschall RR, Kearns GL, Leeder JS: Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54. [PubMed:11717173]
External Links
Human Metabolome Database
HMDB14742
KEGG Drug
D00274
KEGG Compound
C06910
PubChem Compound
6917698
PubChem Substance
46504980
ChemSpider
5292927
BindingDB
50005836
ChEBI
3720
ChEMBL
CHEMBL560739
Therapeutic Targets Database
DAP000222
PharmGKB
PA449011
IUPHAR
240
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cisapride
ATC Codes
A03FA02 — Cisapride
MSDS
Download (74.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4TerminatedTreatmentDiabetes Mellitus (DM) / Gastroparesis1
4TerminatedTreatmentGastroparesis1
4TerminatedTreatmentInfants, Premature / Newborn Infants1
4TerminatedTreatmentReflux, Gastroesophageal1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Janssen pharmaceutica products lp
Packagers
Dosage forms
FormRouteStrength
SuspensionOral1 mg
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5648093No1994-07-152014-07-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)110 °CNot Available
water solubility2.71 mg/LNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP2.95ALOGPS
logP2.49ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)14.58ChemAxon
pKa (Strongest Basic)8.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.05 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity122.93 m3·mol-1ChemAxon
Polarizability49.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9666
Blood Brain Barrier+0.9383
Caco-2 permeable+0.5835
P-glycoprotein substrateSubstrate0.8103
P-glycoprotein inhibitor IInhibitor0.5422
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.5978
CYP450 2C9 substrateNon-substrate0.8718
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7375
CYP450 1A2 substrateNon-inhibitor0.6912
CYP450 2C9 inhibitorNon-inhibitor0.8868
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.8269
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.524
Ames testNon AMES toxic0.6505
CarcinogenicityNon-carcinogens0.8915
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0806 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8918
hERG inhibition (predictor II)Inhibitor0.8616
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0980000000-a0df861122e90da3494b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0159-0710900000-262b97df953edaab4cfa

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzamides. These are organic compounds containing a benzamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Aminobenzamides
Alternative Parents
3-halobenzoic acids and derivatives / Aminophenyl ethers / Benzamides / Methoxyanilines / Anisoles / Phenoxy compounds / Benzoyl derivatives / Methoxybenzenes / Alkyl aryl ethers / Chlorobenzenes
show 15 more
Substituents
Aminobenzamide / Halobenzoic acid or derivatives / 3-halobenzoic acid or derivatives / Aminophenyl ether / Methoxyaniline / Benzamide / Phenoxy compound / Anisole / Methoxybenzene / Aniline or substituted anilines
show 33 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, organofluorine compound, aromatic ether, substituted aniline, benzamides, monochlorobenzenes (CHEBI:3720)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR4
Uniprot ID
Q13639
Uniprot Name
5-hydroxytryptamine receptor 4
Molecular Weight
43760.975 Da
References
  1. Crema F, Modini C, Croci T, Langlois M, de Ponti F: Intestinal prokinesia by two esters of 4-amino-5-chloro-2- methoxybenzoic acid: involvement of 5-hydroxytryptamine-4 receptors and dissociation from cardiac effects in vivo. J Pharmacol Exp Ther. 1999 Mar;288(3):1045-52. [PubMed:10027842]
  2. Nagakura Y, Akuzawa S, Miyata K, Kamato T, Suzuki T, Ito H, Yamaguchi T: Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999 May;39(5):375-82. [PubMed:10328995]
  3. Rahme MM, Cotter B, Leistad E, Wadhwa MK, Mohabir R, Ford AP, Eglen RM, Feld GK: Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation. 1999 Nov 9;100(19):2010-7. [PubMed:10556228]
  4. Bharucha AE, Camilleri M, Haydock S, Ferber I, Burton D, Cooper S, Tompson D, Fitzpatrick K, Higgins R, Zinsmeister AR: Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut. 2000 Nov;47(5):667-74. [PubMed:11034583]
  5. Bach T, Syversveen T, Kvingedal AM, Krobert KA, Brattelid T, Kaumann AJ, Levy FO: 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol. 2001 Feb;363(2):146-60. [PubMed:11218067]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nagakura Y, Akuzawa S, Miyata K, Kamato T, Suzuki T, Ito H, Yamaguchi T: Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999 May;39(5):375-82. [PubMed:10328995]
  2. Talley NJ: Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther. 1992 Jun;6(3):273-89. [PubMed:1600046]
  3. de Ridder WJ, Schuurkes JA: Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors. J Pharmacol Exp Ther. 1993 Jan;264(1):79-88. [PubMed:8093733]
  4. Haga N, Suzuki H, Shiba Y, Mochiki E, Mizumoto A, Itoh Z: Effect of TKS159, a novel 5-hydroxytryptamine4 agonist, on gastric contractile activity in conscious dogs. Neurogastroenterol Motil. 1998 Aug;10(4):295-303. [PubMed:9697104]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Nieto JE, Snyder JR, Kollias-Baker C, Stanley S: In vitro effects of 5-hydroxytryptamine and cisapride on the circular smooth muscle of the jejunum of horses. Am J Vet Res. 2000 Dec;61(12):1561-5. [PubMed:11131599]
  2. Cushing DJ, Cohen ML: Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity. J Pharmacol Exp Ther. 1993 Jan;264(1):193-200. [PubMed:8423526]
  3. Beubler E, Coupar IM, Hardcastle J, Hardcastle PT: Stimulatory effects of 5-hydroxytryptamine on fluid secretion and transmural potential difference in rat small intestine are mediated by different receptor subtypes. J Pharm Pharmacol. 1990 Jan;42(1):35-9. [PubMed:1969947]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, Qiu MR, Breit SN, Campbell TJ: Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol. 1999 Sep;128(2):444-50. [PubMed:10510456]
  2. Chen J, Seebohm G, Sanguinetti MC: Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12461-6. Epub 2002 Sep 3. [PubMed:12209010]
  3. Lin J, Guo J, Gang H, Wojciechowski P, Wigle JT, Zhang S: Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels. Mol Pharmacol. 2005 Sep;68(3):855-65. Epub 2005 Jun 20. [PubMed:15967876]
  4. Perrio M, Voss S, Shakir SA: Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf. 2007;30(4):333-46. [PubMed:17408310]
  5. Mohammad S, Zhou Z, Gong Q, January CT: Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 1997 Nov;273(5 Pt 2):H2534-8. [PubMed:9374794]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Pearce RE, Gotschall RR, Kearns GL, Leeder JS: Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54. [PubMed:11717173]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:40